We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
No fiscal-year history available for this company yet.
No P/E, the company is not profitable on a trailing basis.
J-Pharma Co., Ltd. is engaged in drug discovery and development, focusing on amino acid transporters as drug targets. The company researches and develops drugs targeting solute carrier (SLC) transporters, with emphasis on the LAT1 amino acid transporter. It is developing several compounds for various medical indications, including JPH034 for central nervous system demyelinating diseases and multiple sclerosis. The company conducts functional and structural analysis of selected SLC transporters to support drug discovery, collaborates with academic institutions, and participates in joint research for new pharmaceutical development. It is preparing for clinical trials and global distribution of its drug candidates. The company was founded in 2005 and is based in Yokohama, Japan.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 520A.T and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
